A Review of Selumetinib in the Treatment of Neurofibromatosis Type 1-Related Plexiform Neurofibromas.

Objective: To evaluate the safety and efficacy of selumetinib, a novel MEK inhibitor, for the treatment of plexiform neurofibromas (PN) in patients with neurofibromatosis type 1 (NF1).

Data Sources: An English-based literature search of PubMed, EMBASE, and ClinicalTrials.gov was conducted using the terms AND from inception to August 1, 2021.